CPDR Patient Education Program
Industry-Sponsored Clinical Trials and Projects
The CRC maintains a comprehensive portfolio of both investigator-initiated and industry sponsored clinical trials that cover the entire patient's "life cycle." Some of the trials, though industry sponsored, are investigator-initiated trials for which a proposal was submitted by CPDR to obtain funding. All trials and projects are carried out with full approval of the respective IRBs.
CPDR Open Clinical Trials
ProstAtak TrialA randomized trial of ProstAtak in combination with standard external beam radiation therapy with or without androgen deprivation therapy is in men with intermediate to high risk localized prostate cancer. ProstAtak is an investigational product that is meant to kill tumor cells and elicit an anti-tumor vaccine effect. In a Phase II clinical trial of ProstAtak given with radiation, prostate cancer recurrence was three-fold lower than typically seen with radiation alone. The purpose of this Phase III trial is to definitively determine if ProstAtak reduces prostate cancer recurrence
BAYER - RADIUM 223A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride (radium 223 dichloride is FDA approved drug that targets prostate cancer in the bones), in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer
AMOR3-SVA phase 3, randomized, open-label, multi-center, controlled study of Galeterone compared to Enzalutamide in men expressing androgen receptor splice variant-7 mRNA (AR-V7) with metastatic (M1) castrate resistant prostate cancer (CRPC). Galeterone is a selective, multi-targeted, small molecule drug for the treatment of castrate resistant prostate cancer
CONTACT Information: Judith A. Travis, RN, Walter Reed National Military Medical Center, Center for Prostate Disease Research, America Building 19, Room 3225 on the 3rd floor.
301-319-2927 or Judith.firstname.lastname@example.org
May 28, 2016
Highlights at the 2016 AUA Annual Meeting in San Diego, Ca
The Center for Prostate Disease Research (CPDR) multi-disciplinary team - together with collaborators - presented 13 abstracts in moderated poster or podium presentations at the American Urological Association (AUA) Annual Meeting, May 6-10, 2016, San Diego, CA. The team was co-led by COL David McLeod, (Ret), MD, CPDR Director and Professor of the Department of Surgery, Uniformed Services University of the Health Sciences (USU) and the Walter Reed National Military Medical Center (WRNMMC); Dr. Shiv Srivastava, CPDR Co-Director and Professor in the Department of Surgery at USU and WRNMMC; COL Inger Rosner, MD, Associate Director, CPDR and Associate Professor, Department of Surgery, USU and the WRNNMC; Dr. Jennifer Cullen, Director of Epidemiology Research Program, CPDR and Research Assistant Professor, Department of Surgery, USU and WRNMMC and Dr. Albert Dobi, Associate Director, CPDR and Research Assistant Professor, Department of Surgery , USU and WRNMMC.
May 13, 2016
CPDR Student Participant Wins The AACR Gary J. Miller Undergraduate Prize for Cancer and Cancer Related Biomedical Research
A third place prize in the AACR Undergraduate Student Caucus and Poster Competition was awarded to Ms. Shahnoza Dusmatova, a CPDR participant in the DoD "Research and Education Program for Historically Black Colleges and Universities and Minority-Serving Institutions (HBCU/MI)".
May 2, 2016
CPDR Presentations and Highlights at the 2016 AACR Annual Meeting in New Orleans, La.
The Center for Prostate Disease Team has presented their new findings in prostate cancer research at the American Association for Cancer Research Annual Meeting 2016 in New Orleans, Louisiana, USA.
The Team led by Dr. David G. McLeod, Director and Dr. Shiv Srivastava, Co-Director presented the ground breaking discovery of the first recurrent cancer genomic defect of prostate cancers of African American men revealed by whole genome sequencing. The title of the poster presentation was “LSAMP gene deletion is associated with rapid disease progression in prostate cancer of African American men”.
or go to theWRNMMC UsToo! Newsletter Archive
Read the JUNE 2016 CPDR E-Newsletter